PDS Biotechnology Corp 8-K

What Happened

• PDS Biotechnology Corporation (PDSB) announced on June 15, 2026 that it closed the financing described in its April 30, 2026 Securities Purchase Agreement with YA II PN, Ltd. The company issued a promissory note with an aggregate face value of $6,000,000 (purchased for $5,760,000) and a warrant to buy up to 2,158,274 shares of common stock. The closing also included a guaranty by PDS Operating Corporation and the filing of a Registration Rights Agreement.
• Concurrently, PDS entered a Sales Agreement with Yorkville Securities, LLC (an affiliate of the investor) and B. Riley Securities, Inc. to sell up to $50,000,000 of common stock through an “at‑the‑market” (ATM) program under its effective Form S‑3 registration statement.

Key Details

• Promissory Note: $6,000,000 face value issued June 15, 2026 for a purchase price of $5,760,000; 12‑month maturity; 10% annual interest (subject to increase on default); contains customary conversion, amortization, redemption and beneficial ownership limits.
• Warrant: exercisable beginning six months after closing, for five years, to purchase up to 2,158,274 shares at $1.1824 per share (subject to adjustments); includes customary beneficial‑ownership and cashless exercise provisions.
• ATM Sales Agreement: up to $50,000,000 of shares may be sold at the company’s discretion through Yorkville and B. Riley; agents’ commission is 3.0% of gross proceeds; B. Riley acts as the qualified independent underwriter.
• Other: Company repaid and terminated prior indebtedness as a condition of closing; a registration statement filing obligation exists to register shares issuable on conversion/exercise.

Why It Matters

• Liquidity and near‑term obligation: The financing provides immediate cash (net of purchase discount) but creates a 12‑month, 10% interest obligation that the company must repay or convert within a year. The note’s terms and guarantee mean the company has short‑term debt to manage.
• Potential dilution and share availability: The warrant could add up to ~2.16 million shares if exercised, and the ATM program allows up to $50M of new common stock to be sold into the market, both of which could dilute existing shareholders if exercised or sold.
• Use of proceeds: Any net proceeds from ATM sales are first required to be applied to amortization payments under the promissory note, with remaining proceeds available for working capital and general corporate purposes—so future equity sales may be used to service this debt.